Search PubMed⌕ Search

Biomedical subjects

S Seidl

Publications and source records attributed to S Seidl.

At least 55 records · Page 3Linked to original sources
PubMed1992

[Gene amplification with PCR and sequence specific HLA oligonucleotide typing].

Genetic polymorphism in the HLA class II region has been identified by the analysis of the polymerase chain reaction (PCR) products using sequence-specific oligonucleotide (SSO). The PCR-SSO method permits precise and direct analysis of allelic variations with as little as 1 microgram of genomic DNA. The standardized, uniform hybridization and critical wash protocol of the Eurotransplant typing kit enables HLA typing independent of gene expression and quality of lymphocytes. One of the advantages of this technique is that the definition of splits is much better than typing by serology.

Base Sequence↗
PubMed1992

[Development of HLA antibodies in thrombocyte substitution with cell separator products].

In a retrospective study we investigated the development of HLA antibodies in patients who received platelet concentrates from cell separators. 118 hematological/oncological patients from the Frankfurt University Clinics were investigated. They received between 4 and 66 platelet concentrates for the duration of 30 months. All patients had a negative antibody screening on admission. 31% developed either transient (15%) or permanent (16%) lymphocytotoxic antibodies. The increasing number of platelet transfusions did not correlate with the development of HLA antibodies, but the appearance of these antibodies seemed to be dependent on the disease. Permanent antibodies appeared in 8% of patients with acute leukemia, whereas 38% of patients suffering from CL, lymphoma, MDS and myeloma produced antibodies. Some patients (18) received granulocyte transfusions as well. It is striking that 11% of these patients developed permanent and 28% transient HLA antibodies. There exist no data about recent transfusions or previous pregnancies. To lower the rate of sensitization in patients with diseases such as CL, lymphoma, MDS and myeloma, it should be discussed whether leukocyte-depleted platelet concentrates should be given to these patients.

Blood Component Transfusion↗
PubMed1992

[Decreasing the risk of post-transfusion non-A, non-B hepatitis by anti-HCV screening].

In May 1990 a specific enzyme immunoassay (EIA) for NANBH was developed by recombinant DNA technology which detects antibodies to a virus called hepatitis C virus (HCV). The anti-HCV EIA was manufactured by Ortho Diagnostic Systems with recombinant antigens from Chiron Corp. based on extraction from high infectious titer chimpanzee plasma RNA after transcription into cDNA. We tested the anti-HCV prevalence of blood donors and hemodialysis patients. The anti-HCV prevalence with the first generation test was 0.52% (Ortho), 0.87% (Abbott) in blood donors and 4.16% in hemodialysis patients. The second generation anti-HCV test (Abbott) with improved sensitivity and specificity comprises 0.25% repeated anti-HCV-positive blood donors and 8.2% anti-HCV-positive hemodialysis patients.

Blood Donors↗
PubMed1992

[Prevention of post-transfusion non-A, non-B hepatitis by anti-HCV screening].

Since May 1990 a specific enzyme immunoassay (EIA) for NANBH has been developed by recombinant DNA technology which detects antibodies to a virus called hepatitis C virus (HCV). The anti-HCV EIA was manufactured by Ortho-Diagnostic Systems with recombinant antigens from Chiron Corp. based on extraction from high infectious titre chimpanzee plasma RNA after transcription into cDNA. We tested the anti-HCV prevalence of blood donors and hemodialysis patients. The anti-HCV prevalence with the first generation test was 0.52% (Ortho), 0.87% (Abbott) in blood donors and 4.16% in hemodialysis patients. The second generation anti-HCV test (Abbott) with improved sensitivity and specificity comprises 0.25% repeated anti-HCV positive blood donors and 8.2% anti-HCV positive hemodialysis patients.

Antigens, Viral↗
PubMed1992

[Gene amplification with PCR and sequence-specific HLA oligotyping].

Genetic polymorphism in the HLA-class II region has been identified by the analysis of the polymerase-chain reaction (PCR) products using sequence-specific oligonucleotide (SSO). The PCR-SSO method permits precise and direct analysis of allelic variations with as little as 1 microgram of genomic DNA. The standardized, uniform hybridization and critical wash protocol of the Eurotransplant-typing kit [2] enables HLA-typing independent of gene expression and lymphocytes quality. One of the advantages of this technique is that the definition of subtypes is much better than is typing by serology.

Amino Acid Sequence↗
PubMed1991

The HLA-DQ beta non-Asp-57 allele: a predictor of future insulin-dependent diabetes mellitus in patients with autoimmune Addison's disease.

HLA-DR specificities in 72 Addison's (AD) patients and 808 local controls were compared. We confirmed earlier reports that the HLA-DR3 specificity is significantly increased in AD patients. In our study a relative risk of 3.4 chi 2 = 22.5; pc = 0.01) for the disease was calculated. Analysis of HLA-DQB1 alleles in DR4+ Addison's patients with diabetes mellitus (N = 6) and without IDDM (14 of 18 individuals tested) revealed that the HLA-DQw8 allele (DQB1*0302) was significantly increased in AD patients with IDDM (chi 2 = 13.5; p = 0.001); conversely, a clustering of the HLA-DQw7 allele was detected in DR4+ Addison's patients without IDDM. We thus conclude that particular polymorphic alleles corresponding to non-charged amino acids at position 57 of the HLA-DQ beta-chain [non-Asp-57 alleles] are associated with IDDM also in Addison's patients.

Addison Disease↗
PubMed1991

The in vitro and in vivo evaluation of whole blood and red cell concentrates drawn on CPDA-1 and stored in a non-DEHP plasticized PVC container.

A new polyvinyl chloride (PVC) blood storage container, PL 2209, plasticized with butyryl-n-trihexyl-citrate (BTHC) instead of diethylhexyl phthalate (DEHP) was used for in vitro and in vivo studies. Whole blood and red cell concentrates drawn on CPDA-1 were stored 42 days at 1-6 degrees C. Various biochemical parameters were tested and compared to those values seen in the literature for products stored in DEHP-plasticized containers. Measurements of lactate production, glucose consumption, sodium and potassium ions for both whole blood and red cells were compatible with published data. Adenosine triphosphate (ATP) values were on the average 73% for the red cell units and 80% for the whole blood units after 35 days storage. Hemolysis was 0.43% for the red cell concentrate and 0.38% for the whole blood units after the same storage period. Autologous recovery studies after 35 days of storage for both the whole blood units and red cell concentrate gave 80% recovery 24 h after reinjection. From these data it can be concluded that PL 2209 BTHC-plasticized PVC blood storage containers allow 35 days storage of blood draw on CPDA-1 and can be considered as an alternative to DEHP-plasticized PVC containers.

Adenine↗
PubMed1991

Epidemiology and immunogenetic background of islet cell antibody--positive nondiabetic schoolchildren. Ulm-Frankfurt population study.

Islet cell antibodies (ICAs) were determined in a large cohort of white nondiabetic schoolchildren (n = 4287) from a homogenous population in southern Germany. The prevalence of ICA levels greater than or equal to 5 Juvenile Diabetes Foundation (JDF) U was 1.05% (95% confidence interval 0.8-1.4%). Analysis of HLA-DR beta and -DQ beta alleles revealed that the specificities found to be increased in insulin-dependent (type I) diabetic subjects with the same ethnic background were also associated with ICA positivity in the nondiabetic schoolchildren. HLA-DR3 (P less than 0.01) and -DR4 (P less than 0.01) phenotypes and absence of Asp residue (P less than 0.01) at codon 57 of the HLA-DQ beta-chain were significantly increased in ICA+ compared with control subjects. High levels of ICAs, which were categorized as either greater than or equal to 17 or greater than or equal to 30 JDF U, were found to be associated with amino acids other than Asp at position 57 of the HLA-DQ beta-chain. No association of ICA level was found for HLA-DR phenotypes.

Adolescent↗
PubMed1990

[Search for bone marrow donors for patients with hematologic-oncologic diseases].

In recent years, bone marrow transplantation (BMT) has been used as a curative treatment for patients with intractable hematopoietic disorders, such as leukemia. However, lacking other options, only 30 percent of patients will have an HLA-identical family-member bone marrow donor. For patients without HLA-identical family members, HLA-identical, MLC non-reactive unrelated donors have been used. However it is very difficult to find HLA-compatible donors from an unrelated donor registry, due to the highly polymorphic HLA-system. Therefore, we need approximately 6-12 months to find an HLA-matched donor who would agree to donate bone marrow.

Bone Marrow Transplantation↗
PubMed1990

[Hepatitis C virus antibodies (HCV) in patients treated with chronic hemodialysis].

Patients undergoing chronic hemodialysis are frequently affected by nosocomial viral infections, as indicated by the high prevalence of HBV antibodies. The question, to what extent HCV is transmitted by blood transfusions (NANB-PTH), or acquired in a nosocomial manner, is still unanswered. We therefore evaluated the HCV antibody rate of 387 sera of dialysis patients on the "Eurotransplant" waiting list. The HCV antibody reactivity ranged from 5.4 to 12.0% between different dialysis centers. In highly immunized (HLA antibody positive) long-term dialysis patients 31.3% (vs. 8.3% in non-immunized patients) were HCV antibody positive.

Antibodies, Viral↗
PubMed1990

[Immune hematologic diagnosis in women with habitual abortion].

It has been proposed that unexplained recurrent miscarriages are caused by maternal immune rejection of the semi-allogenic fetus. The problem has been treated by immunization with paternal leukocytes to induce maternal antipaternal-antibodies that may block immune rejection of the fetus. It has been suggested that excessive sharing of HLA antigens predisposes couples to recurrent abortion. However, we did not find evidence for excessive HLA-sharing. The degree of sharing did not differ significantly between the couples with recurrent miscarriages and controls with successful pregnancies.

Abortion, Habitual↗
PubMed1990

[Hepatitis C antibodies in non-A, non-B hepatitis patients and members of HIV risk groups (pilot study)].

In a multi-center study sera from NANB-hepatitis (NANBH) patients and members of so-called HIV-risk groups (homosexuals, i.v.-drug abusers, hemophiliacs) were investigated by the recombinant-based HCV-antibody EIA, 74.4% of chronic NANBH-patients and 20% of acute NANBH patients were anti-HCV reactive, 33.3% of HIV-1-positive homosexuals, 43.5% of i.v.-drug abusers and 73.5% of hemophiliacs. The true prevalence of infection remains to be determined by a second, independent (confirmatory) test.

Antibodies, Viral↗
PubMed1990

[CMV antibody determination with two enzyme immunoassays in each case].

In each of the two present studies (Frankfurt blood donor center and blood bank of the university of Hamburg) two commercial enzyme immunoassay (EIA) test kits for detecting cytomegalovirus (CMV) antibodies were compared according to their concordance. In the Frankfurt study, 448 sera of blood donors and patients were tested for IgG- and IgM-specific antibodies by CMV-ELA Test (Medac); IgG-specific antibodies were tested in 3 serum dilutions (1:10, 1:100, 1:1000) of each sample, 221 sera were additionally assayed using the EIA of ABBOTT. Both methods showed the same results in 214/221 (96.8%) sera (p less than 0.001). The determination of CMV-IgG-specific antibody levels were as follows: Out of 294 seropositive individuals, titers greater than or equal to 1:1000 were seen in 81% (238). IgM antibodies to CMV were determined in 22/448 serum specimen, which all had IgG antibodies too; there were 18/22 (81.8%) samples with elevated titers for CMV-IgG (greater than or equal to 1:1000). In the second study, 500 sera of blood donors from Hamburg were tested for CMV-IgG antibodies by two enzyme immunoassays, CMV-IgG-ELA (Medac) and Anti-CMV-IgG-ELISA (Biotest). The results were concordant in 418 (83.6%) of the 500 samples (p less than 0.01). All EIA procedures were found to be convenient test methods for CMV antibody screening and the results showed significant correlations. Furthermore, the determination of CMV-IgG-specific antibodies seems to be sufficient for routine CMV screening in blood donor centers.

Antibodies, Viral↗
PubMed1990

[Significance of cytomegalovirus in blood donation].

The subjects of the present study are diagnostic and epidemiologic aspects in the determination of serum antibodies to cytomegalovirus in blood donors, organ donors, dialysis patients and drug addicts (some of whom were HIV-positive); antibodies were determined using the ELA-Test (CMV-IgG ELA and CMV-IgM-ELA). 221 sera were additionally assayed using the CMV total AB EIA which has been used in the Frankfurt blood center since May 1985 for CMV antibody screening of blood donors: both enzyme immunoassays showed the same results in 214 sera (96.8%), which shows a high rate of correlation (requiv = 0.99, p less than 0.001). The groups were found to be CMV antibody positive as follows: blood donors 65/102 (63.7%), organ donors 10/13 (76.9%), dialysis patients 88/106 (83.0%), drug addicts 131/227 (57.7%), and HIV-antibody-positive drug addicts 17/31 (54.8%). There was a significant statistical difference between blood donors and dialysis patients (p less than 0.01); the difference between blood donors and drug addicts was also statistically significant when age was considered (p less than 0.001). There was no statistical significance in the distinction between HIV-negative and HIV-positive drug addicts. IgM-specific antibodies were found in 1/102 (0.98%) blood donors, 18/106 (17.0%) dialysis patients and 3/227 (1.3%) drug addicts, whereas in organ donors no IgM-specific antibodies were determined. The seropositivity rate of a Frankfurt group of regular blood donors (n = 1826) was 55.5%.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗
PubMed1990

[Hepatitis C virus (HCV) antibodies in German blood donors--a pilot study].

A new EIA-test to detect Hepatitis C antibody (ORTHO Diagnostic Systems) has been evaluated in four blood transfusion services in FRG (Hamburg, Hannover, Springe, Frankfurt). Among 3,123 specimens, 18 (0.58%) reacted initially positive, 13 (0.42%) remained positive after repeat testing. A detailed analysis revealed remarkable differences: blood donors from the northern part of Germany were less frequently positive than donors from the southern region (0.24% vs. 0.79%), repeat donors had a higher HCV-antibody incidence than first-time donors (0.48% vs. 0.29%). Similar differences were observed between remunerated and non-remunerated donors (0.24% vs. 0.53%), as well as between donors from rural and urban areas (0.34% vs. 0.46%). In contrast to other investigators, only a weak correlation between elevated ALT-levels (greater than 50 IU/ml) and anti-HCV seropositivity rate has been found.

Antigens, Viral↗